
HF-POLARIS

zenagamtide | effects on heart failure outcomes in people with obesity

National Data Package



Taiwan

National Leader:



Tsung-Hsien Lin

novo nordisk®


Participant overview

Screening in Taiwan will start in September 2026

Participant overview	Overall recruitment target	Participants screened	Participants randomised	Screen failure rate*	Off treatment
	N	N	N	%	N
Taiwan	35	0	0	0	0
Global	5,610	1,064	438	46	12

**Forecasted*

Participants randomised and recruitment target in Taiwan in 2026



Screen failure reasons

Screen failure reasons	Global*
	N (%)
NT-proBNP (I7)	153 (38)
HF decompensation/ eGFR/UACR (I8)	104 (26)
Investigator discretion (E31)	22 (5)
HbA_{1c} >10% (E12)	12 (3)
LVEF (I5)	12 (3)
Diabetic retinopathy (E10)	10 (3)
ICF process (I1)	8 (2)
BMI (I3)	8 (2)
Malignancy history (E22)	7 (2)
Insulin therapy (E11)	6 (2)
Other	64 (16)

**Globally, 34 participants (13%) failed due to more than one eligibility criteria*
BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA_1C, glycated haemoglobin; HF, heart failure; ICF, Informed Consent Form; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal B-type natriuretic peptide.

Site-level data

Planned number of sites: 5

Site*	PI	Participants, N			
		Screened	In screening	Screen failed	Randomised

**Only sites that have actively started recruitment are included*

Notes

Notes

What are the challenges you face or anticipate facing concerning:



Recruitment?



Retention?



Collaboration with other stakeholders?

Are there any challenges in other areas that you'd like to address in your action plan?

What actions or initiatives can you implement to help resolve these issues?